BioSpace News Archive

Innate Pharma SA announced that updated preclinical data on its IPH6501 tetra-specific ANKET® are presented at the European Hematology Association 2023 congress.

BioArctic AB’s partner Eisai announced that the U.S. Food and Drug Administration’s Peripheral and Central Nervous System Drugs Advisory Committee voted unanimously that the data from Eisai’s Phase 3 Clarity AD clinical trial confirms the clinical benefit of LEQEMBI® 100 mg/mL intravenous injection for the treatment of Alzheimer’s disease.

Nkarta, Inc. announced presentations highlighting preliminary data based on a November 2022 data cut-off from its Phase 1 dose escalation clinical trial of NKX019 at two scientific conferences: the European Hematology Association 2023 Hybrid Congress and the 17th International Conference on Malignant Lymphoma.

Celldex Therapeutics, Inc. announced that updated data from the Company’s Phase 1b multi-dose clinical trial in chronic spontaneous urticaria and new data from the Phase 1b single-dose cholinergic cohort included in the chronic inducible urticaria trial were presented at the European Academy of Allergy and Clinical Immunology Annual Congress 2023.

Pharvaris announced two presentations highlighting data from RAPIDe-1, a Phase 2 study of PHVS416 for the on-demand treatment of HAE attacks, included in the “Flash Talks on Angioedema” session at the European Academy of Allergy & Clinical Immunology Hybrid Congress 2023, taking place in Hamburg, Germany, from June 9-11, 2023.

HOOKIPA Pharma Inc. announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-statutory options to new employees to purchase an aggregate of 80,000 shares of the Company’s Common Stock under HOOKIPA’s 2023 Inducement Plan.

Gracell Biotechnologies Inc. presented longer-term follow-up data from a first-in-human study evaluating GC012F, a CD19 and B-cell maturation antigen dual-targeted autologous CAR-T therapeutic candidate, in patients with relapsed/refractory B-cell non-Hodgkin’s Lymphoma as an oralpresentation at the European Hematology Association Congress.

Aptose Biosciences Inc. released highlights from a clinical update event held, June 10, 2023, in conjunction with EHA 2023 International Congress of the European Hematology Association in Frankfurt, Germany.

Biovica International Biovica announces that it has signed a provider contract with Contigo Health ConfigureNet™ provider network.

Ocular Therapeutix, Inc. announced 12-month data from its Phase 1 U.S. clinical trial evaluating OTX-TKI, the Company’s axitinib intravitreal hydrogel implant, for the treatment of wet age-related macular degeneration.